Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2021 | Deep Genomics | Series C | 0 |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 3/2017 | EGenesis | Series A | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 12/2022 | SonoThera | Series A | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 10/2017 | Visterra | Series C | 0 |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 6/2018 | StrideBio | Series A | 15.7M |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 10/2017 | Cydan | Venture Round | 34M |
| 7/2021 | IgGenix | Series A | 0 |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 3/2022 | Creyon Bio | Series A | 0 |
| 9/2018 | OncoResponse | Series B | 40M |
| 6/2020 | Element Biosciences | Series B | 30M |
| 1/2021 | AltPep | Series A | 23.1M |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2017 | Halio | Series C | 65M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 11/2019 | Genetron Health | Series D | 71M |
| 4/2018 | QurAlis | Seed Round | - |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 5/2021 | Marvin | Seed Round | 0 |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 5/2021 | miRecule | Venture Round | 0 |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 10/2021 | DNA Script | Series C | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 11/2018 | Ribometrix | Series A | 30M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 6/2018 | Cibus | Series C | 70M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 2/2021 | Ensoma | Series A | 0 |
| 4/2019 | Insitro | Series A | 100M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2020 | Dren Bio | Series A | 0 |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 3/2021 | StrideBio | Series B | 0 |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 1/2023 | Ensoma | Series B | 0 |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2022 | TRex Bio | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 12/2022 | Dantari | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Benson Hill | Series C | 65M |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 11/2022 | Rezo | Series A | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 7/2022 | Xilis | Series A | 0 |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 1/2022 | Avalo | Convertible Note | 750k |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 6/2022 | Dren Bio | Series B | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 4/2021 | SeQure DX | Series A | 0 |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 1/2021 | Encodia | Series C | 75M |
| 7/2021 | Wugen | Series B | 0 |
| 9/2022 | Novome | Series B | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 8/2021 | Humacyte | PIPE | 175M |
| 10/2021 | Immunai | Series B | 215M |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 5/2021 | Inari | Series D | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 6/2021 | TRex Bio | Series A | 59M |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 9/2021 | Kytopen | Series A | 0 |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 4/2023 | Function Oncology | Series A | 28M |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 8/2018 | Inari | Series B | 40M |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 12/2018 | Kallyope | Series B | 21M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 3/2019 | Gencove | Seed Round | 3M |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
